Journal of Medicinal Chemistry · 2009 · 53 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsEnzyme InhibitionMtor Inhibitor TherapyPotency OptimizationStereochemical OptimizationStructure-activity Relationship AnalysisActive Site InhibitorsCompound Potency OptimizationMedicinal Chemistry ApplicationsMixed-type InhibitorsMtor InhibitionPhosphatidylinositol 3-Kinase PathwayPyrimidine AnaloguesSelectivity
Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase alpha (PI3K-alpha), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC(50) against mTOR and greater than 1000-fold selectivity over PI3K-alpha. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC(50) < 1 nM) with unprecedented activity in cellular proliferation assays (IC(50) < 1 nM).
23
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
Dos D. Sarbassov, David A. Guertin, Siraj M. Ali et al. · Science · 2005 · 6.2K citations
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Zachary A. Knight, Beatriz González, Morri E. Feldman et al. · Cell · 2006 · 1.2K citations · Full text
Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +13